

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version 1.1                      Revision Date: 06-16-2020                      Date of last issue: 06-15-2020  
 Date of first issue: 06-15-2020

**SECTION 1. IDENTIFICATION**

Product name : PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)  
 Product code : RO719-8574/F03  
 Common name(s), synonym(s) of the substance : HERCEPTIN® (Trastuzumab), PERJETA® (Pertuzumab) Trastuzumab, Pertuzumab Fixed Dose Combination (40mg/ml, 80mg/ml) Loading Dose

**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.  
 Address : DNA Way 1  
 94080 South San Francisco  
 CA  
 USA  
 Telephone : 001-(650) 225-1000  
 E-mail address : info.sds@roche.com  
 Emergency telephone : US Chemtrec phone (800)-424-9300  
 Emergency telephone number

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance  
 Restrictions on use : For professional users only.

---

**SECTION 2. HAZARDS IDENTIFICATION**
**GHS classification in accordance with 29 CFR 1910.1200**

Not a hazardous substance or mixture.

**GHS label elements**

Not a hazardous substance or mixture.

**Other hazards**

None known.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Trastuzumab	180288-69-1	4.0
Pertuzumab	380610-27-5	8.0
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	4.56
Trehalose (D+)-, 2H2O	6138-23-4	2.65

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**
Version  
1.1Revision Date:  
06-16-2020Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

L-Histidine monohydrochloride monohydrate	5934-29-2	0.36
L-Histidine	71-00-1	0.05
L-Methionine	63-68-3	0.15
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.04
Hyaluronidase	757971-58-7	0.003
Water	7732-18-5	> 80.0

---

**SECTION 4. FIRST AID MEASURES**

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.  
If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.  
Remove contact lenses.  
Protect unharmed eye.  
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.  
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:  
Carbon monoxide  
Nitrogen oxides (NO<sub>x</sub>)
- Further information : Standard procedure for chemical fires.

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
Keep in suitable, closed containers for disposal.

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Pertuzumab	380610-27-5	IOEL	0.04 mg/m <sup>3</sup>	Roche Industrial Hygiene Com-

# SAFETY DATA SHEET

## PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

				mittee (RIHC)
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0
Trastuzumab	180288-69-1	IOEL	0.1 mg/m3	Roche Industrial Hygiene Committee (RIHC)
Hyaluronidase	757971-58-7	IOEL	0.00006 mg/m3	Roche Industrial Hygiene Committee (RIHC)

**Engineering measures** : No data available

### Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

Material : Protective gloves

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Sterile liquid, Clear liquid

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version 1.1                      Revision Date: 06-16-2020                      Date of last issue: 06-15-2020  
 Date of first issue: 06-15-2020

Color	:	colorless, light brown
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	5.5
Melting point/range	:	No data available
Boiling point/boiling range	:	No data available
Evaporation rate	:	No data available
Self-ignition	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**Version  
1.1Revision Date:  
06-16-2020Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution

Possibility of hazardous reactions : Stable under recommended storage conditions.  
No hazards to be specially mentioned.

Conditions to avoid : No data available

Incompatible materials : No data available

Hazardous decomposition products : No data available

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified based on available information.

**Components:****Pertuzumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

LD50 Oral (Mouse): 14,000 mg/kg

Acute inhalation toxicity : Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist  
Method: Expert judgmentAcute dermal toxicity : Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment**Trastuzumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : Maximum tolerated dose (Mouse): > 94 mg/kg  
Application Route: i.v.**Hyaluronidase:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Hyaluronidase:**

Remarks : This information is not available.

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:**

**Hyaluronidase:**

Remarks : This information is not available.

**Respiratory or skin sensitization**

**Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:**

**Hyaluronidase:**

Remarks : May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

**Germ cell mutagenicity**

Not classified based on available information.

**Carcinogenicity**

Not classified based on available information.

**Components:**

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified based on available information.

**Components:**

**Trastuzumab:**

Effects on fetal development : Result: Parenteral administration to pregnant women can cause fetal harm

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**Version  
1.1Revision Date:  
06-16-2020Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020**STOT-single exposure**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**Hyaluronidase:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Hyaluronidase:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Repeated dose toxicity****Components:****Pertuzumab:**Species : cynomolgus monkey  
NOAEL : mg/kg/w, 250  
Application Route : s.c.  
Exposure time : 4 Weeks  
GLP : yes  
Remarks : Subacute toxicitySpecies : cynomolgus monkey  
: 50 mg/kg/w  
Application Route : i.v.  
Exposure time : 26 Weeks  
GLP : yes  
Remarks : Subchronic toxicity**Hyaluronidase:**Species : cynomolgus monkey  
NOAEL : mg/kg/w, 2  
Application Route : s.c.  
Exposure time : 39 weeks



**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**Version  
1.1Revision Date:  
06-16-2020Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020**Aspiration toxicity**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

**Hyaluronidase:**

No data available

**Further information****Components:****Pertuzumab:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : Health injuries are not known or expected under normal use.

**Trastuzumab:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Toxicity to fish : LC50: > 100 mg/l  
Exposure time: 96 h

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**Version  
1.1Revision Date:  
06-16-2020Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020**Hyaluronidase:****Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Persistence and degradability****Components:****Pertuzumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Trastuzumab:**Biodegradability : Result: Readily biodegradable.  
Biodegradation: 65 %  
Exposure time: 14 d  
Method: OECD Test Guideline 301F  
GLP: yes

Result: Globular proteins are generally well biodegradable

**Hyaluronidase:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****Pertuzumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Partition coefficient: n-octanol/water : log Pow: -3.67

**Trastuzumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Hyaluronidase:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Mobility in soil**

No data available

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

**Other adverse effects**

**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

**Components:**

**Pertuzumab:**

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

**Trastuzumab:**

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

**Hyaluronidase:**

Additional ecological information : No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation**

**49 CFR**

Not regulated as a dangerous good

**SECTION 15. REGULATORY INFORMATION**

**EPCRA - Emergency Planning and Community Right-to-Know**

**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

**SARA 311/312 Hazards** : No SARA Hazards

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

**US State Regulations**

**Massachusetts Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**Pennsylvania Right To Know**

Water	7732-18-5
Pertuzumab	380610-27-5
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1
Trastuzumab	180288-69-1

**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

**Maine Chemicals of High Concern**

**Vermont Chemicals of High Concern**

**Washington Chemicals of High Concern**

**California Permissible Exposure Limits for Chemical Contaminants**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**The ingredients of this product are reported in the following inventories:**

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Pertuzumab

Trastuzumab

L-Histidine monohydrochloride monohydrate

Hyaluronidase

AICS : Not in compliance with the inventory

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Substance(s) not listed on TSCA inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

---

**SECTION 16. OTHER INFORMATION**


**PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)**

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

**NFPA:**



**HMIS® IV:**

<b>HEALTH</b>	/	<b>0</b>
<b>FLAMMABILITY</b>		<b>0</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- ACGIH : USA. ACGIH Threshold Limit Values (TLV)
- NIOSH REL : USA. NIOSH Recommended Exposure Limits
- OSHA P0 : USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
- OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- ACGIH / TWA : 8-hour, time-weighted average
- NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- OSHA P0 / TWA : 8-hour time weighted average
- OSHA Z-1 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

## PHESGOTM(pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80/40mg/ml)

Version  
1.1

Revision Date:  
06-16-2020

Date of last issue: 06-15-2020  
Date of first issue: 06-15-2020

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06-16-2020

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810